Drugs Health Pharma

Teva to sell generic version of Novo Nordisk’s diabeticĀ drug in US

Israel’s Teva Pharmaceuticals will start selling a generic version of Novo Nordisk’s type 2 diabetic drug Victoza in the US market.

Read More
Drugs Health Pharma

Novo Nordisk to set up $4.1 billion injectables facility in US’s North Carolina

Novo Nordisk, a Danish pharmaceutical multinational, will invest $4.1 billion to build a new factory in the US to make obesity and chronic.

Read More
Drugs Health Pharma

WHO issues medical alert on falsified weight-loss, diabetic drugs

The World Health Organization has issued a medical product alert on falsified semaglutides, an active ingredient in Ozempic, a diabetic drug made by.

Read More
Drugs Health Pharma

FDA panel rejects Novo Nordisk’s weekly jab to treat type 1 diabetes

The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA refused approval for a once-weekly jab to control blood sugar levels in people.

Read More
Drugs Health Pharma

Novo Nordisk raises sales forecast on strong demand for anti-obesity drug

HQ Team May 2, 2024: Novo Nordisk, Europe’s most valuable company, has raised its 2024 revenue outlook on the back of its popular.

Read More
Drugs Health Pharma

Viking Therapeutics’ weight-loss drug shows ā€˜positive’ results in early trials

US-based biotechnology company Viking Therapeutics Inc., reported ā€œpositiveā€ results from its early-stage weight-loss oral drug and the pill showed mild to moderate side.

Read More
Drugs Health Pharma

Novo to buy Cardior for $1.1b to expand cardiovascular segment

HQ Team March 25, 2024: Novo Nordisk, one of the world’s most valuable companies, will acquire Germany-based Cardior Pharmaceuticals, a firm that specialises.

Read More
Drugs Health Pharma

Novo Nordisk unveils new drug to fight obesity, says 13% effective

HQ Team March 11, 2024: Danish drugmaker Novo Nordisk’s oral medicine, amycretin, for obesity can cause up to 13% weight loss, the company.

Read More
Drugs Health Pharma

Novo Nordisk says Ozempic reduces kidney disease progressionĀ 

HQ Team March 6, 2024: Novo Nordisk’s diabetes drug Ozempic delayed the progression of kidney disease and cardiovascular and kidney deaths in 24%.

Read More
Drugs Health Pharma

Novo Nordisk buys 3 Catalent sites for $11bn to meet rising demand for Wegovy

HQ Team February 5, 2024: Novo Nordisk will acquire three manufacturing sites in an $11bn deal to expand its production of weightless drugs.

Read More